These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19731022)

  • 1. Statin therapy and serum transaminases among a cohort of HCV-infected veterans.
    Henderson LM; Patel S; Giordano TP; Green L; El-Serag HB
    Dig Dis Sci; 2010 Jan; 55(1):190-5. PubMed ID: 19731022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of statin hepatotoxicity in patients with hepatitis C.
    Khorashadi S; Hasson NK; Cheung RC
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):902-7; quiz 806. PubMed ID: 16697272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.
    Segarra-Newnham M; Parra D; Martin-Cooper EM
    Pharmacotherapy; 2007 Jun; 27(6):845-51. PubMed ID: 17542767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
    Chalasani N; Aljadhey H; Kesterson J; Murray MD; Hall SD
    Gastroenterology; 2004 May; 126(5):1287-92. PubMed ID: 15131789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.
    Kim HS; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Kim SH; Choi IY; Yoon KH; Kim JH
    J Clin Pharm Ther; 2016 Jun; 41(3):266-72. PubMed ID: 27015878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.
    Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B;
    J Hepatol; 2014 Jan; 60(1):46-53. PubMed ID: 23978720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
    Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis.
    Mohanty A; Tate JP; Garcia-Tsao G
    Gastroenterology; 2016 Feb; 150(2):430-40.e1. PubMed ID: 26484707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study.
    Clement ME; Park LP; Navar AM; Okeke NL; Pencina MJ; Douglas PS; Naggie S
    Clin Infect Dis; 2016 Aug; 63(3):407-13. PubMed ID: 27143663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.
    Zuckerman E; Zuckerman T; Douer D; Qian D; Levine AM
    Cancer; 1998 Sep; 83(6):1224-30. PubMed ID: 9740089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans.
    Sutton SS; Magagnoli J; Cummings TH; Hardin JW
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):103-112. PubMed ID: 32239436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.
    Smith CC; Bernstein LI; Davis RB; Rind DM; Shmerling RH
    Arch Intern Med; 2003 Mar; 163(6):688-92. PubMed ID: 12639201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.
    Pandya P; Rzouq F; Oni O
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):555-65. PubMed ID: 25835493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine deaminase activity in serum of patients with hepatitis -- a useful tool in monitoring clinical status.
    Kaya S; Cetin ES; Aridogan BC; Arikan S; Demirci M
    J Microbiol Immunol Infect; 2007 Aug; 40(4):288-92. PubMed ID: 17712462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis.
    Fabrizi F; Lunghi G; Finazzi S; Colucci P; Pagano A; Ponticelli C; Locatelli F
    Am J Kidney Dis; 2001 Nov; 38(5):1009-15. PubMed ID: 11684554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia.
    Desai NK; Mendelson MM; Baker A; Ryan HH; Griggs S; Boghani M; Yellen E; Buckley L; Gillman MW; Zachariah JP; Graham D; Jonas MM; de Ferranti SD
    J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):175-181. PubMed ID: 30334928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring statin safety in primary care.
    Tragni E; Filippi A; Mazzaglia G; Sessa E; Cricelli C; Catapano AL
    Pharmacoepidemiol Drug Saf; 2007 Jun; 16(6):652-7. PubMed ID: 17300133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.
    Pastori D; Pani A; Di Rocco A; Menichelli D; Gazzaniga G; Farcomeni A; D'Erasmo L; Angelico F; Del Ben M; Baratta F
    Br J Clin Pharmacol; 2022 Feb; 88(2):441-451. PubMed ID: 34133035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.